Shin Shinyama1, Tatsuru Kaji1, Motoi Mukai1, Kazuhiko Nakame1, Hiroshi Matsufuji2, Hideo Takamatsu3, Satoshi Ieiri4. 1. Department of Pediatric Surgery, Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area, Research and Education Assembly, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. 2. Ambulatory Care Center for Children, St. Luke's International Hospital, Tokyo, Japan. 3. Research and Education Assembly, Kagoshima University, Kagoshima, Japan. 4. Department of Pediatric Surgery, Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area, Research and Education Assembly, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. sieiri@m.kufm.kagoshima-u.ac.jp.
Abstract
PURPOSE: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease of premature infants. Daikenchuto, a Japanese herbal drug, has several effects on the digestive system, so we investigated its preventive effects in a rat model of NEC. METHODS: NEC was induced in newborn rats via asphyxia (100% N2 for 90 s; every 4 h) + LPS (4 mg/kg/day [administered orally on days 0 and 1]). The effects of Daikenchuto were evaluated in four groups (control: 0 g/kg/day, I: 0.3 g/kg/day, II: 0.6 g/kg/day, and III: 1.0 g/kg/day). Daikenchuto was administered into the stomach through a microcatheter. The incidence and severity of NEC were pathologically assessed using the NEC grade in accordance with Dovorak's previous report. Cell positivity for inflammatory cytokine (IL-6) was also evaluated. RESULTS: Daikenchuto reduced the incidence of NEC in control, Groups I, II, and III to 68.7, 30.0, 30.7, and 13.3%, respectively. High-dose Daikenchuto significantly improved the incidence of NEC, and the rate of IL-6 positive cells in group III was significantly lower than in the control group (p = 0.04). CONCLUSION: We evaluated the effect of Daikenchuto against NEC and found that it reduced the incidence rate of NEC due to a decrease in the IL-6 production.
PURPOSE:Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease of premature infants. Daikenchuto, a Japanese herbal drug, has several effects on the digestive system, so we investigated its preventive effects in a rat model of NEC. METHODS: NEC was induced in newborn rats via asphyxia (100% N2 for 90 s; every 4 h) + LPS (4 mg/kg/day [administered orally on days 0 and 1]). The effects of Daikenchuto were evaluated in four groups (control: 0 g/kg/day, I: 0.3 g/kg/day, II: 0.6 g/kg/day, and III: 1.0 g/kg/day). Daikenchuto was administered into the stomach through a microcatheter. The incidence and severity of NEC were pathologically assessed using the NEC grade in accordance with Dovorak's previous report. Cell positivity for inflammatory cytokine (IL-6) was also evaluated. RESULTS: Daikenchuto reduced the incidence of NEC in control, Groups I, II, and III to 68.7, 30.0, 30.7, and 13.3%, respectively. High-dose Daikenchuto significantly improved the incidence of NEC, and the rate of IL-6 positive cells in group III was significantly lower than in the control group (p = 0.04). CONCLUSION: We evaluated the effect of Daikenchuto against NEC and found that it reduced the incidence rate of NEC due to a decrease in the IL-6 production.
Entities:
Keywords:
Daikenchuto; IL-6; NEC grade; Necrotizing enterocolitis; Rat model
Authors: Bohuslav Dvorak; Melissa D Halpern; Hana Holubec; Catherine S Williams; Debra L McWilliam; Jessica A Dominguez; Renata Stepankova; Claire M Payne; Robert S McCuskey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-01 Impact factor: 4.052
Authors: Rebecca Maria Rentea; Scott R Welak; Katherine Fredrich; Deborah Donohoe; Kirkwood A Pritchard; Keith T Oldham; David M Gourlay; Jennifer L Liedel Journal: Eur J Pediatr Surg Date: 2012-11-19 Impact factor: 2.191
Authors: Melissa D Halpern; Hana Holubec; Jessica A Dominguez; Catherine S Williams; Yolanda G Meza; Debra L McWilliam; Claire M Payne; Robert S McCuskey; David G Besselsen; Bohuslav Dvorak Journal: Pediatr Res Date: 2002-06 Impact factor: 3.756